Brannagan, Thomas H. III
Auer-Grumbach, Michaela
Berk, John L.
Briani, Chiara
Bril, Vera
Coelho, Teresa
Damy, Thibaud
Dispenzieri, Angela
Drachman, Brian M.
Fine, Nowell
Gaggin, Hanna K.
Gertz, Morie
Gillmore, Julian D.
Gonzalez, Esther
Hanna, Mazen
Hurwitz, David R.
Khella, Sami L.
Maurer, Mathew S.
Nativi-Nicolau, Jose
Olugemo, Kemi
Quintana, Luis F.
Rosen, Andrew M.
Schmidt, Hartmut H.
Shehata, Jacqueline
Waddington-Cruz, Marcia
Whelan, Carol
Ruberg, Frederick L. http://orcid.org/0000-0002-6424-4413
Funding for this research was provided by:
Akcea Therapeutics
Article History
Received: 22 September 2020
Accepted: 20 April 2021
First Online: 6 May 2021
Declarations
:
: Not applicable.
: Not applicable.
: Michaela Auer-Grumbach: Speaker honoraria from Pfizer, Akcea Therapeutics, Biogen, Sanofi-Genzyme, Roche, CSL Behring and Novartis; Scientific Advisory Board participation with Akcea Therapeutics, Biogen, Sanofi-Genzyme, Roche, CSL Behring and Novartis; Research support from Pfizer, Biogen, Sanofi-Genzyme and Roche. John L. Berk: Consulting honoraria from Alnylam Pharmaceutical, Akcea Therapeutics, Ionis Pharmaceutical, and Scientific Advisory Board participation with Intellia Therapeutics and Corino Therapeutics. Thomas H Brannagan III: Consulting income from Akcea, Alnylam, Ionis, and Pfizer; institution has received clinical trial funding from Alnylam and Ionis. Chiara Briani: Speaker and consulting honoraria from Akcea, Alnylam, and Pfizer and travel grants from Kedrion, Alnylam, and CSL Behring. Vera Bril: Consultant for CSL, Grifols, Octapharma, UCB, Argenx, Takeda, Alnylam, Ionis, Akcea, Alexion, Immunovant, and Momenta, and Sanofi; research support: CSL, Grifols, Octapharma, UCB, Argenx, Takeda, Ionis, Akcea, Alexion, Immunovant, and Momentaand Sanofi. Teresa Coelho: Speaker and consultant honoraria and financial support to attend scientific meetings from Pfizer, Alnylam, Ionis, Akcea, Biogen and Prothena. Institution received clinical trial and research funding from Pfizer, Alnylam, Ionis, Prothena and Eidos. Thibaud Damy: Consulting honoraria and research support from Akcea, Alnylam, Neurimmune and Pfizer. Angela Dispenzieri: Trial support: Pfizer, Alnylam, Takeda, and Celgene; advisory board: Akcea, Janssen. Brian M. Drachman: Consulting/advisory board member for Eidos and Alnylam. Nowell Fine: Consulting honoraria and research support from Akcea Alnylam and Pfizer. Hanna K. Gaggin: Research grant support from Roche Diagnostics, Jana Care, Ortho Clinical, Novartis, Pfizer, Alnylam, and Akcea; consulting income from Amgen, Eko, Merck, Roche Diagnostics, Radiometer, and Pfizer; stock ownership for Eko; research payments for clinical endpoint committees from Radiometer. She has also received research payment for clinical endpoint committees from Baim Institute for Clinical Research for Abbott, Siemens, and Beckman Coulter. Morie Gertz: Personal fees from Ionis/Akcea, Alnylam, Prothena, Janssen, Annexon, Appellis, Amgen, Medscape, Physician’s Education Research, Data Safety Monitoring board from AbbVie and Celgene, Research to Practice, workforce training Sanofi; grants and personal fees from Spectrum; speaker fees from Teva, Johnson and Johnson, Medscape, DAVA oncology; advisory board for Pharmacyclics, Proclara; Development of educational materials for i3Health; Educational Program development for i3Health Royalties from Springer Publishing; Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation; NCI SPORE MM SPORE 5P50 CA186781-04; and stock options for Aurora Bio. Julian D. Gillmore: Advisory Board member for Alnylam, Akcea, Eidos, and Pfizer. Esther Gonzalez: Speaking fees from Pfizer and Alnylam. Consulting fees from Pfizer, Akcea Therapeutics and Proclara. Research support to her institution from Pfizer, Eidos, and Alnylam. Mazen Hanna: Advisory board for Pfizer, Eidos, Akcea and Alnylam. David R. Hurwitz: Employee of Akcea Therapeutics. Sami L. Khella: Consultant for Eidos and Pfizer. Mathew S. Maurer: Reports grant support from National Institutes of Health [R01HL139671-01], [R21AG058348] and [K24AG036778]; consulting income from Pfizer, GSK, Eidos, Prothena, Akcea, and Alnylam; institution received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Jose Nativi-Nicolau: Institution received funding for clinical trials for Pfizer, Akcea, and Eidos and Educational Grants from Pfizer; consultant for Pfizer, Eidos, Akcea, and Alnylam. Kemi Olugemo: Employee of Akcea Therapeutics. Luis F. Quintana: Nothing to disclose. Andrew M. Rosen: Employee of Akcea Therapeutics. Hartmut H. Schmidt: Nothing to disclose. Jacqueline Shehata: Employee of Akcea Therapeutics. Marcia Waddington-Cruz: Received honorarium from NHI, Prothena, FoldRx, Ionis, Pfizer, Alnylam, PTC and Genzyme for travel expenses related to presentations at medical meetings, for acting as a principal investigator in clinical trials and as a consultant member. Carol Whelan: Advisory board member Alnylam and Akcea. Frederick L. Ruberg: Research support from NIH (HL139671), Pfizer, Eidos Therapeutics, and Akcea Therapeutics.